JP2023549455A5 - - Google Patents
Info
- Publication number
- JP2023549455A5 JP2023549455A5 JP2023524333A JP2023524333A JP2023549455A5 JP 2023549455 A5 JP2023549455 A5 JP 2023549455A5 JP 2023524333 A JP2023524333 A JP 2023524333A JP 2023524333 A JP2023524333 A JP 2023524333A JP 2023549455 A5 JP2023549455 A5 JP 2023549455A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- apiteglomab
- treatment
- human subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063105850P | 2020-10-26 | 2020-10-26 | |
| US63/105,850 | 2020-10-26 | ||
| US202063106172P | 2020-10-27 | 2020-10-27 | |
| US63/106,172 | 2020-10-27 | ||
| US202163200955P | 2021-04-05 | 2021-04-05 | |
| US63/200,955 | 2021-04-05 | ||
| US202163201157P | 2021-04-15 | 2021-04-15 | |
| US63/201,157 | 2021-04-15 | ||
| US202163202317P | 2021-06-06 | 2021-06-06 | |
| US63/202,317 | 2021-06-06 | ||
| US202163202372P | 2021-06-08 | 2021-06-08 | |
| US63/202,372 | 2021-06-08 | ||
| US202163202900P | 2021-06-29 | 2021-06-29 | |
| US63/202,900 | 2021-06-29 | ||
| US202163260725P | 2021-08-30 | 2021-08-30 | |
| US63/260,725 | 2021-08-30 | ||
| US202163261398P | 2021-09-20 | 2021-09-20 | |
| US63/261,398 | 2021-09-20 | ||
| PCT/US2021/056517 WO2022093724A1 (en) | 2020-10-26 | 2021-10-25 | Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549455A JP2023549455A (ja) | 2023-11-27 |
| JP2023549455A5 true JP2023549455A5 (enExample) | 2024-10-10 |
Family
ID=78622120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023524333A Pending JP2023549455A (ja) | 2020-10-26 | 2021-10-25 | 脊髄性筋萎縮症を治療するための抗プロミオスタチン／抗潜在型ミオスタチン抗体の使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240002490A1 (enExample) |
| EP (2) | EP4729069A1 (enExample) |
| JP (1) | JP2023549455A (enExample) |
| KR (1) | KR20230095998A (enExample) |
| CN (1) | CN116390756A (enExample) |
| AU (1) | AU2021369471A1 (enExample) |
| CA (1) | CA3193909A1 (enExample) |
| ES (1) | ES3058087T3 (enExample) |
| IL (1) | IL302132A (enExample) |
| MX (1) | MX2023004763A (enExample) |
| PL (1) | PL4232151T3 (enExample) |
| TW (1) | TW202233234A (enExample) |
| WO (1) | WO2022093724A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20211081T1 (hr) | 2015-09-15 | 2021-10-15 | Scholar Rock, Inc. | Anti-pro/latentna miostatinska protutijela i njihove uporabe |
| DK4518970T3 (da) | 2022-05-04 | 2026-04-07 | Scholar Rock Inc | Anvendelse af myostatinhæmmer til behandling af spinal muskelatrofi |
| EP4638496A1 (en) | 2022-12-22 | 2025-10-29 | Scholar Rock, Inc. | Selective and potent inhibitory antibodies of myostatin activation |
| WO2026076383A1 (en) | 2024-10-06 | 2026-04-09 | Scholar Rock, Inc. | Use of myostatin inhibitor for treating spinal muscular atrophy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040044063A1 (en) | 2002-05-31 | 2004-03-04 | Brent Stockwell | SMA therapy and cell based assay for identifying therapies |
| JP2010523684A (ja) | 2007-04-12 | 2010-07-15 | パラテック ファーマシューティカルズ インコーポレイテッド | テトラサイクリン化合物を用いる、脊髄筋委縮症を治療するための方法 |
| HRP20211081T1 (hr) | 2015-09-15 | 2021-10-15 | Scholar Rock, Inc. | Anti-pro/latentna miostatinska protutijela i njihove uporabe |
| NZ789269A (en) | 2016-06-13 | 2026-01-30 | Scholar Rock Inc | Use of myostatin inhibitors and combination therapies |
-
2021
- 2021-10-25 AU AU2021369471A patent/AU2021369471A1/en active Pending
- 2021-10-25 US US18/250,489 patent/US20240002490A1/en active Pending
- 2021-10-25 CA CA3193909A patent/CA3193909A1/en active Pending
- 2021-10-25 EP EP25209770.4A patent/EP4729069A1/en active Pending
- 2021-10-25 CN CN202180071515.9A patent/CN116390756A/zh active Pending
- 2021-10-25 ES ES21807468T patent/ES3058087T3/es active Active
- 2021-10-25 MX MX2023004763A patent/MX2023004763A/es unknown
- 2021-10-25 PL PL21807468.0T patent/PL4232151T3/pl unknown
- 2021-10-25 JP JP2023524333A patent/JP2023549455A/ja active Pending
- 2021-10-25 WO PCT/US2021/056517 patent/WO2022093724A1/en not_active Ceased
- 2021-10-25 KR KR1020237016836A patent/KR20230095998A/ko active Pending
- 2021-10-25 TW TW110139566A patent/TW202233234A/zh unknown
- 2021-10-25 IL IL302132A patent/IL302132A/en unknown
- 2021-10-25 EP EP21807468.0A patent/EP4232151B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023549455A5 (enExample) | ||
| NORRIS JR et al. | The administration of guanidine in amyotrophic lateral sclerosis | |
| US10092564B2 (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| ES3029536T3 (en) | Formulation comprising fenfluramine and cannabidiol and its use in the treatment of seizures | |
| DelRosso et al. | Clinical efficacy and safety of intravenous ferric carboxymaltose treatment of pediatric restless legs syndrome and periodic limb movement disorder | |
| AU2010260585B2 (en) | Compositions and methods for treatment of Multiple Sclerosis | |
| TW202128183A (zh) | 用於治療多種病症之方法及組成物 | |
| JP4234439B2 (ja) | Ｉｌ−１２発現調節剤 | |
| Lin et al. | Subacute combined degeneration caused by nitrous oxide intoxication | |
| Kim et al. | Guillain-Barre syndrome after two COVID-19 vaccinations: two case reports with follow-up electrodiagnostic study | |
| US20180221315A1 (en) | Combination therapy using acamprosate and d-cycloserine | |
| Servais et al. | FIREFISH part 2: efficacy and safety of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA) | |
| Oettmeier et al. | The procainebase-infusion: 20 years of experience of an alternative use with several therapeutical effects | |
| JP2024539148A5 (enExample) | ||
| US6172053B1 (en) | Injection viral treatment | |
| JPH08512311A (ja) | 慢性疲労症候群治療用ヒ素医薬 | |
| JP2024531799A5 (enExample) | ||
| JP2024543347A5 (enExample) | ||
| JP2021088571A (ja) | 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療 | |
| JP2019517516A (ja) | Ｓｍａの新規な処置 | |
| Chand et al. | SMA–THERAPY: P. 256 Intravenous (IV) onasemnogene abeparvovec for spinal muscular atrophy (SMA): integrated safety report | |
| CN117243948A (zh) | 包含瑞香素的组合物在制备风湿性关节炎药物中的应用 | |
| US20240238221A1 (en) | Tapentadol for treating neuropathic pain in covid-19 patients | |
| Płusa | Antiviral treatments for unvaccinated patients against SARS-CoV-2 | |
| JP2026508357A (ja) | 脊髄性筋萎縮症を処置するための組成物及び方法 |